EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage.

ABSTRACT:

Background

This study investigates how sorafenib induces toxicity in glomerular cells and examines the protective role of 8,9-epoxyeicosatrienoic acid (8,9-EET) analogs in reducing this kidney damage.

Methods

Human renal mesangial cells (HRMCs) and podocytes were treated with no treatment, sorafenib alone, or sorafenib combined with 8,9-EET analogs. Cell viability and apoptosis were measured in both cell types.

Results

Sorafenib (1-10 µM) lowered cell viability and increased caspase 3/7 activity in a dose-dependent way in HRMCs and podocytes. Five of twenty 8,9-EET analogs significantly enhanced cell survival and decreased apoptosis. RNA sequencing showed that sorafenib altered 1244 genes, including those involved in cell cycle and the Raf/MEK/ERK pathway. The 8,9-EET

SUBMITTER: Mishra A 

PROVIDER: S-EPMC12467510 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature